Literature DB >> 12789618

Drug therapy for amyotrophic lateral sclerosis: Where are we now?

Gregory T Carter1, Lisa S Krivickas, Patrick Weydt, Michael D Weiss, Robert G Miller.   

Abstract

In the 60 years since Lou Gehrig died from amyotrophic lateral sclerosis (ALS) there have been numerous advances in our understanding of this disease. However, scant progress has been made regarding disease-altering treatments. Today most physicians still recommend vitamin E, which is the treatment Gehrig himself received. In this paper we will review what is currently known about the pathophysiology of ALS as well as the history of clinical trials in ALS. We indicate current and future directions in research and clinical trials, and also argue that a logical next step for clinical trials in ALS should be combination drug treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12789618

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  3 in total

1.  Dosing medical marijuana: rational guidelines on trial in Washington State.

Authors:  Sunil K Aggarwal; Muraco Kyashna-Tocha; Gregory T Carter
Journal:  MedGenMed       Date:  2007-09-11

Review 2.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

Review 3.  Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis.

Authors:  Yves Lecarpentier; Alexandre Vallée
Journal:  Front Neurol       Date:  2016-06-28       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.